EU Crunch Time Nears For Amgen’s Novel Lung Cancer Drug Sotorasib
Executive Summary
The European Medicines Agency is expected to make recommendations on EU marketing authorization for 10 new medicines at its monthly meeting this week. They include products for non-small cell lung cancer, COVID-19, kidney disease, smallpox and migraine.
You may also be interested in...
EMA Greenlights Ronapreve & Regkirona For COVID-19 In EU
The European Commission is likely to act rapidly on the formal approval of coronavirus treatments casirivimab/imdevimab and regdanvimab.
EMA Schedules High-Stakes Oral Explanation Meeting For Aducanumab Filing
The sponsors of aducanumab and three other drugs are set to explain why their EU marketing authorization applications merit approval during oral explanation meetings at the European Medicines Agency.
EMA Schedules High-Stakes Oral Explanation Meeting For Aducanumab Filing
The sponsors of aducanumab and three other drugs are set to explain why their EU marketing authorization applications merit approval during oral explanation meetings at the European Medicines Agency.